X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs CADILA HEALTHCARE - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA CADILA HEALTHCARE SANOFI INDIA/
CADILA HEALTHCARE
 
P/E (TTM) x 32.8 32.6 100.7% View Chart
P/BV x 6.3 6.5 96.8% View Chart
Dividend Yield % 1.4 0.7 198.0%  

Financials

 SANOFI INDIA   CADILA HEALTHCARE
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
CADILA HEALTHCARE
Mar-17
SANOFI INDIA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs4,560460 991.3%   
Low Rs4,400305 1,442.6%   
Sales per share (Unadj.) Rs1,028.592.1 1,116.6%  
Earnings per share (Unadj.) Rs129.014.8 870.4%  
Cash flow per share (Unadj.) Rs186.018.5 1,006.4%  
Dividends per share (Unadj.) Rs68.003.20 2,125.0%  
Dividend yield (eoy) %1.50.8 181.4%  
Book value per share (Unadj.) Rs753.668.0 1,108.5%  
Shares outstanding (eoy) m23.031,023.74 2.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.2 104.9%   
Avg P/E ratio x34.725.8 134.6%  
P/CF ratio (eoy) x24.120.7 116.4%  
Price / Book Value ratio x5.95.6 105.7%  
Dividend payout %52.721.6 244.1%   
Avg Mkt Cap Rs m103,174391,581 26.3%   
No. of employees `0003.616.9 21.5%   
Total wages/salary Rs m3,59215,002 23.9%   
Avg. sales/employee Rs Th6,537.75,594.5 116.9%   
Avg. wages/employee Rs Th991.4890.1 111.4%   
Avg. net profit/employee Rs Th819.8899.9 91.1%   
INCOME DATA
Net Sales Rs m23,68694,295 25.1%  
Other income Rs m7081,286 55.1%   
Total revenues Rs m24,39495,581 25.5%   
Gross profit Rs m5,28119,036 27.7%  
Depreciation Rs m1,3133,750 35.0%   
Interest Rs m15450 3.3%   
Profit before tax Rs m4,66116,122 28.9%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m1,6911,289 131.2%   
Profit after tax Rs m2,97015,168 19.6%  
Gross profit margin %22.320.2 110.4%  
Effective tax rate %36.38.0 453.8%   
Net profit margin %12.516.1 78.0%  
BALANCE SHEET DATA
Current assets Rs m15,67360,223 26.0%   
Current liabilities Rs m6,67853,058 12.6%   
Net working cap to sales %38.07.6 499.8%  
Current ratio x2.31.1 206.8%  
Inventory Days Days7670 108.8%  
Debtors Days Days2288 25.3%  
Net fixed assets Rs m8,09872,984 11.1%   
Share capital Rs m2301,024 22.5%   
"Free" reserves Rs m17,08868,576 24.9%   
Net worth Rs m17,35669,600 24.9%   
Long term debt Rs m024,684 0.0%   
Total assets Rs m25,400152,207 16.7%  
Interest coverage x311.736.8 846.5%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.90.6 150.5%   
Return on assets %11.810.3 114.5%  
Return on equity %17.121.8 78.5%  
Return on capital %26.917.9 150.2%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,14521,280 33.6%   
Fx outflow Rs m6,84610,874 63.0%   
Net fx Rs m29910,406 2.9%   
CASH FLOW
From Operations Rs m3,22613,495 23.9%  
From Investments Rs m-1,555-29,103 5.3%  
From Financial Activity Rs m-1,81823,158 -7.9%  
Net Cashflow Rs m-1477,556 -1.9%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 8.3 173.5%  
FIIs % 14.6 5.9 247.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 11.0 95.5%  
Shareholders   15,184 44,069 34.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   CIPLA  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  PIRAMAL ENTERPRISES  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jan 22, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - ALEMBIC LTD COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS